MetaVia secures 39 patents for obesity drug DA-1726 through 2041 Feb 13, 2026 08:34AM
MetaVia reports AI analysis confirms vanoglipel therapeutic targets Feb 4, 2026 08:02AM
MetaVia announces public offering of up to 1.57 million units Jan 5, 2026 05:06PM
H.C. Wainwright Starts MetaVia (MTVA) at Buy Sep 4, 2025 06:14AM
MetaVia partners with Syntekabio for AI drug discovery collaboration Aug 4, 2025 08:31AM


Jul 2, 2025 04:10PM MetaVia (MTVA) Files for 14.08M Share Offering by Selling Stockholders
May 9, 2025 08:01AM MetaVia (MTVA) Announces $10M Offering at $0.71/sh
Apr 23, 2025 08:31AM MetaVia (MTVA) Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
Apr 22, 2025 08:31AM MetaVia (MTVA) Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726
Apr 15, 2025 07:01AM MetaVia (MTVA) Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726
Dec 30, 2024 06:07AM H.C. Wainwright Starts MetaVia (MTVA) at Buy
Dec 18, 2024 08:01AM MetaVia (MTVA) Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
Nov 18, 2024 08:01AM NeuroBo Pharmaceuticals (NRBO) Announces Strategic Realignment, Changes Name to MetaVia (MTVA)